Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Pharmacoepidemiology and Drug Safety|May 27, 2026
Prevalent-New User Design for Biosimilar Safety Using Saudi Real-World DataOhoud Almadani, Almaha Alfakhri, Ibrahim Asiri, et al.
Journal of Health Economics and Outcomes Research|December 23, 2025
Economic Burden of Alopecia Areata in the Kingdom of Saudi Arabia from a Societal Perspective: A Cost-of-Illness AnalysisKhalidah Alenzi, Abdulrahman Alturaiki, Mohammad Fatani, et al.
Annals of Thoracic Medicine|June 4, 2020
A comparison between warfarin and apixaban: A patient's perspectiveAbdullah U Althemery, Abdullah A Alfaifi, Abdulrahman Alturaiki, et al.
Health Economics Review|January 24, 2026
The economic burden of diabetes-related visual impairment and blindness in Saudi ArabiaGihan Hamdy Elsisi, Abdullah Alhumaidan, Abdulrahman Alturaiki, et al.
Infectious Diseases and Therapy|June 21, 2022
Linezolid vs Vancomycin in Induced ThrombocytopeniaDimah Al-Harbi, Abdulrahman Alturaiki, Ayshah Alshngeetee, et al.
Frontiers in Pharmacology|January 4, 2021
Validation and Psychometric Properties of the Arabic Version of the Duke Anticoagulation Satisfaction Scale (DASS)Maha AlAmmari, Khizra Sultana, Sattam Nawaf AlHarbi, et al.
Advances in Therapy|September 11, 2024
Modeling the Clinical and Economic Burden of Therapeutic Inertia in People with Type 2 Diabetes in Saudi ArabiaMohammed Alluhidan, Abdulrahman Alturaiki, Hana Alabdulkarim, et al.
Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society|March 17, 2026
Comparing the pharmacokinetics of adalimumab originator and biosimilar product in patients with Inflammatory bowel disease or autoimmune diseaseHadeel Drweesh, Amal Alotaibi, Hussain Abdalghani Alqassim, et al.
Pageof 1